Nafloxin (Ciprofloxacin)

Ciprofloxacin, administered as Nafloxin, is a fluoroquinolone antibiotic that targets bacterial DNA replication in a range of serious infections.

• Severe urinary tract infections: eradicates causative Gram‑negative and some Gram‑positive bacteria, relieving infection symptoms.
• Respiratory tract infections: eliminates pathogenic bacteria in pneumonia and bronchitis, improving pulmonary function.
• Intra‑abdominal infections: provides broad‑spectrum coverage against mixed flora, aiding resolution of peritonitis and abscesses.
• Skin and soft tissue infections: treats cellulitis, wound infections and diabetic foot infections by killing susceptible organisms.
• Bone and joint infections: penetrates bone tissue to eradicate osteomyelitis‑causing pathogens.
• Septicemia: rapidly reduces bacterial load in bloodstream infections, supporting hemodynamic recovery.

• Ciprofloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for supercoiling and separation of DNA during replication and transcription. By binding to the ATP‑binding sites of these enzymes, it prevents the relaxation of DNA strands, halting bacterial cell division and leading to bacterial death. This bactericidal action is effective against a broad spectrum of Gram‑negative and some Gram‑positive organisms.

Ciprofloxacin may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, sometimes watery.
• Headache: transient cranial discomfort.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Tendon rupture: sudden tendon pain or rupture, especially Achilles.
• QT prolongation: cardiac rhythm disturbances that may lead to arrhythmia.
• Severe allergic reaction: anaphylaxis with hives, swelling, or breathing difficulty.
• Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption.

When using Nafloxin, clinicians should observe several precautionary measures to minimise risks.

• Renal impairment: adjust therapy and monitor renal function.
• Hepatic dysfunction: use with caution in patients with liver disease.
• Concomitant QT‑prolonging drugs: avoid or monitor cardiac rhythm.
• History of tendon disorders: avoid use in patients with prior tendon injury.
• Pregnancy and lactation: safety not established; weigh benefits against potential risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ciprofloxacin can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption; separate dosing by at least 2 hours.
• Warfarin: increase anticoagulant effect; monitor INR closely.
• Theophylline: raise plasma levels, risk of toxicity.
• Cyclosporine: increase cyclosporine concentrations; monitor levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of CNS stimulation.
• Corticosteroids: heightened risk of tendon rupture.
• Diabetic agents (e.g., insulin, sulfonylureas): may cause hypoglycaemia.
• Oral contraceptives: possible reduction in effectiveness; advise backup method.